Japan Debuts Novel Dry Eye Therapy - Summary - MDSpire

Japan Debuts Novel Dry Eye Therapy

Senju Pharmaceutical launches the first TRPV1 antagonist for dry eye in Japan

  • April 30, 2026

  • 3 min

Share

Objective:

To introduce Avarept, the first marketed dry eye therapy in the TRPV1 antagonist class, in Japan.

Approach:
    Key Findings:
    • Avarept is the first dry eye therapy targeting TRPV1 antagonism.
    • Dry eye disease affects over 20 million people in Japan, with increasing prevalence due to aging and lifestyle factors.
    • Current treatments often provide incomplete relief, highlighting the need for new therapeutic options.
    Interpretation:

    Avarept's introduction marks a significant advancement in dry eye disease management, offering a new mechanism of action that may improve patient outcomes.

    Limitations:
    • The long-term safety and efficacy of Avarept remain to be fully established.
    • The study results are based on a specific population in Japan, which may limit generalizability.
    Conclusion:

    Avarept represents a promising new option for patients suffering from dry eye disease, addressing a critical need for effective therapies.

    Sources:

Original Source(s)

Japan Debuts Novel Dry Eye Therapy

  • April 30, 2026

Related Content

Assessment of the Safety and Effectiveness of Stem Cell Treatments for Dry Eye Syndrome Associated with Sjögren’s Syndrome: A Systematic Review and Meta-Analysis

Study Provides Real-World Evidence for Inflammatory DED

Carolina L. Mercado, MD, and colleagues presented data from the American Academy of Ophthalmology IRIS (Intelligent Research in Sight) Registry linked to pharmacy claims data sourced from the Komodo Health Research Dataset.

Red Eye, Global Challenge

Narrative review calls for clearer guidance on noninfectious conjunctival hyperemia

  • March 18, 2026

  • 2 min